⌕

Gilead Sciences (GILD) vs Vertex Pharmaceuticals (VRTX)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
63
Vertex Pharmaceuticals, Inc.
$538.60 · $137B · as of last close
Highest qualityFastest grower
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is balance sheet.

#2 FIT
61
Gilead Sciences, Inc.
$168.08 · $208B · as of last close
Best incomeCalmest rideBest returns
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is dividend & income.

VRTX barely leads (63/100 vs GILD 61) under a balanced style, mostly on balance sheet. But GILD wins on dividend & income, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorGILDVRTX
Overall fit score
weighted for your balanced goal
61
7 of 8 factors known
✓ 63
Valuation
Cheaper for what you get
1×
P/E — · EV/EBITDA 504.8
TTM through Sep 30, 2026
29
✓ P/E 35 · EV/EBITDA 29.7
P/E trailing
33
Growth
Revenue & earnings momentum
1×
—
58
✓ —
65
Profitability & quality
Margins & return on capital
1×
Net −12% · ROIC −6%
TTM through Sep 30, 2026
53
✓ Net 31% · ROIC 14%
TTM through Sep 30, 2026
71
Total return
Share-price change with dividends reinvested
1×
✓ 5Y +25%/yr
88
5Y +23%/yr
85
Risk (calm = better)
Volatility & drawdown
1×
✓ β 0.3 · DD −27%
97
β 0.5 · DD −29%
92
Balance sheet†
Debt vs cash cushion
1×
Net debt/EBITDA 43.8×
TTM through Sep 30, 2026
10
✓ Net debt/EBITDA −0.4×
TTM through Sep 30, 2026
51
Dividend & income
Cash paid to you
1×
✓ 1.93% yield· B
93
—
40
Analyst sentiment
Forward EPS growth (consensus)
1×
no forward consensus
—
✓ Est EPS +11%/yr · 17 analysts
66
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ GILD■ VRTX
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
GILD−27%0.3225%5Y
VRTX−29%0.4829%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on dividend & income: 1.93% yield (score 93).

▲ Leads on risk (calm = better): β 0.3 · DD −27% (score 97).

BEAR CASE

▼ Weakest on balance sheet (score 10). Net debt/EBITDA 43.8× is one of the 5 inputs.

▼ Weakest on profitability & quality: Net −12% · ROIC −6% (score 53).

BULL CASE

▲ Leads on profitability & quality: Net 31% · ROIC 14% (score 71).

▲ Leads on growth: — (score 65).

BEAR CASE

▼ Weakest on dividend & income: — (score 40).

▼ Weakest on risk (calm = better): β 0.5 · DD −29% (score 92).

WHAT COULD CHANGE THE SCORE
Balance sheetCurrently 10/100 (Net debt/EBITDA 43.8×). Taking it to 100 would lift the balanced score by 13 points, the biggest single move available.
ValuationCurrently 29/100 (P/E — · EV/EBITDA 504.8). Taking it to 100 would lift the balanced score by 10 points, the next biggest.
ValuationCurrently 33/100 (P/E 35 · EV/EBITDA 29.7). Taking it to 100 would lift the balanced score by 8 points, the biggest single move available.
Dividend & incomeCurrently 40/100 (—). Taking it to 100 would lift the balanced score by 7 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.